Entities

Hillary Coe is listed by Vast as Chief Design and Marketing Officer. Design experience includes SpaceX human spaceflight communications and work at Google, Apple and Starlink.

JP Hemingway is listed by Vast as Senior Vice President, Satellite Business Development & Commercialization. Previously held commercial and leadership positions at SES Satellites, O3b Networks and Ciena.

Jesse Leeds is listed by Vast as Vice President, Global Security and Intelligence. Previously led security and crisis management at Match Group and served in U.S. intelligence and law enforcement.

Jim Martz is listed by Vast as Senior Vice President, Special Projects. Engineering experience includes SpaceX, NASA JPL, Muon Space and Zipline, including spacecraft power and avionics.

Karin Kuo is listed by Vast as Chief People Officer. People and talent leader with experience at Relativity Space and Onica and in management consulting.

Kathy Lueders is listed by Vast as Advisor. Former NASA human-spaceflight leader and SpaceX Starbase general manager; published biography also lists the Texas Space Commission vice chair role.

Kris Young is listed by Vast as Chief Operating Officer. Previously led SpaceX Dragon engineering, integration and crewed mission operations, including Demo-2 and Inspiration4.

Kyle Dedmon is listed by Vast as Senior Vice President, Operations. Previously helped develop SpaceX manufacturing facilities for Starlink and its launch and spacecraft programmes.

Lucie Ravelojaona is listed by Vast as Chief of Staff. Engineer with aviation experience at Airbus and responsibility for strategic initiatives.

Marcos Simon is listed by Vast as Vice President, Flight Safety & Mission Assurance. Previously worked on human-spaceflight safety and mission assurance at SpaceX and Blue Origin.

Mark Groskreutz is listed by Vast as Vice President, Propulsion. Propulsion experience includes Honeywell, SpaceX Merlin and Raptor engines, and Ursa Major.

Max Haot is listed by Vast as Chief Executive Officer. Previously founded Launcher, Mevo and Livestream, subsequently acquired by Vast, Logitech and IAC/Vimeo respectively.

Megan McArthur is listed by Vast as Astronaut. Former NASA astronaut with two space missions, including Hubble servicing and a SpaceX Dragon mission.

Melanie Stricklan is listed by Vast as Senior Vice President, Special Programs. Co-founded Slingshot Aerospace and served in the U.S. Air Force before commercial space leadership roles.

Mette Frich is published by Innovation Fund Denmark as Senior Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Molly McCormick is listed by Vast as Principal Engineer. Spaceflight experience includes Crew Dragon certification, Cargo Dragon operations and lunar payload programmes at Honeybee Robotics.

Naoko Yamazaki is listed by Vast as General Manager, Vast Japan GK; Astronaut. Former JAXA astronaut who flew to the International Space Station in 2010 and has Japanese space-policy experience.

Nicole Jordan is listed by Vast as Vice President, Mission Management. Previously NASA operations manager for the Commercial Crew Program, with human-spaceflight mission and engineering experience.

Peter Russell-Clarke is listed by Vast as Advisor. Industrial designer whose work includes Apple devices, facilities, materials and manufacturing processes.

Randy Huang is listed by Vast as Vice President, Avionics. Previously an engineering executive at Pacific Defense and a space-systems engineering leader at Raytheon.

Richard Leshner is listed by Vast as Vice President, Policy and Government Relations. Space-policy experience includes NASA, the White House and Planet Labs.

Sergei Tanygin is listed by Vast as Vice President, Flight Dynamics & GNC. Astrodynamics and guidance experience includes STK and SpaceX launch-vehicle and spacecraft programmes.

Shane Cioni is listed by Vast as Vice President, Manufacturing. Manufacturing and integration experience includes SpaceX, Virgin Orbit and Relativity Space.

Sid Hariharan is listed by Vast as Chief Financial Officer. Investment banking experience at Rothschild and J.P. Morgan includes mergers, public offerings and capital raising.

Steve Isakowitz is listed by Vast as Advisor. Previously led The Aerospace Corporation and held senior positions at Virgin Galactic, NASA and the U.S. Department of Energy.

Sunita Williams is listed by Vast as Astronaut. Retired NASA astronaut and U.S. Navy captain with extensive orbital mission, command and spacewalk experience.

Tom Shelley is listed by Vast as Vice President, Crew Partnerships. Previously president of Space Adventures, with experience arranging and delivering private astronaut flights.

Will Heltsley is listed by Vast as Advisor. Previously SpaceX vice president of propulsion, with work on Merlin and Raptor engines.

Matilde Bødker Verdoes is published by Innovation Fund Denmark as Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Mathias Holm Tveen is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Martin Søndergaard is published by Innovation Fund Denmark as Head of Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Martha Broegaard Simonsen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Marie Louise Lund Stentoft is published by Innovation Fund Denmark as HR Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Marion Søvndal de Wit is published by Innovation Fund Denmark as Analytics Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Marie Friis Madsen is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Maja Kofod Dam-Jensen is published by Innovation Fund Denmark as Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Maija Strala Ibsen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Magnus Ugilt Rasmussen is published by Innovation Fund Denmark as Analytics Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Mads Trabjerg Kamp is published by Innovation Fund Denmark as Intern. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Lise Skjødt Sørensen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Line Skouboe is published by Innovation Fund Denmark as Communication Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Lene Skovsgaard is published by Innovation Fund Denmark as Head of HR & Organisation. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Lars Zederkof is published by Innovation Fund Denmark as Head of Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Lakshna Arunasalam is published by Innovation Fund Denmark as Finance Officer (Parental leave). This affiliation is listed in the institution’s October2026 public employee directory; the institution explicitly marks the person as on parental leave. the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Kristoffer Nørmark Thrane is published by Innovation Fund Denmark as Intern. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Kristian Tommy Solberg Ambrosius is published by Innovation Fund Denmark as Student Assistant, Økonomi. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Kristian Søndergaard Hansen is published by Innovation Fund Denmark as Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Klaus Bruun Gunnestrup is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Katrine Boeriis is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Jesper Lykkeberg Sørensen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Jens Bech-Larsen is published by Innovation Fund Denmark as Head of Jura & Compliance. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Gustav Rømsgaard is published by Innovation Fund Denmark as Student Assistant, International & Missioner. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Jakob Schmidt Sejling is published by Innovation Fund Denmark as Student Assistant. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Jasper Kloster Pingel is published by Innovation Fund Denmark as Legal Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Stefan Fyhn Gregersen is listed by the Lundbeck Foundation as Member of the Board. Employee-elected foundation director representing Falck since2026. Advanced emergency-medical-technician training and published Falck Denmark board affiliation.

Henrik Sindal Jensen is listed by the Lundbeck Foundation as Member of the Board. Employee-elected foundation director representing H.Lundbeck since2022. Chemistry BSc, molecular-biology MSc and neuroscience PhD; pharmaceutical business-development experience.

Katja Barnkob is listed by the Lundbeck Foundation as Member of the Board. Employee-elected foundation director representing ALK since2022. Pharmaceutical CMC-development project leader with published ALK board affiliation.

Mikkel Helmer Nielsen is listed by the Lundbeck Foundation as Member of the Board. Employee-elected foundation director representing Falck since2022, with technology and emergency-service governance experience.

Eva Hansen is published by Innovation Fund Denmark as Head of Executive Secretariat, Communication & External Relations. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Eva Ladekjær Larsen is published by Innovation Fund Denmark as Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Emma Kloster Nikolajsen is published by Innovation Fund Denmark as Legal Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Elsebeth Hansen is published by Innovation Fund Denmark as Compliance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Ditte Schmidt Jeppesen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Thomas Mrsic-Flogel is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2026 and research/prize committee member. Sainsbury Wellcome Centre director/UCL neuroscience professor; systems-neuroscience, sensory-processing, learning and decision-making research.

Nawal Ouzren is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2025 and investment-committee member. UTC chemical-engineering MSc; Sensorion CEO with clinical-development and pharmaceutical management experience.

Svend Andersen is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2020 and investment-committee member. Business/economics and business-administration education; international pharmaceutical leadership and advisory experience in women’s health and CNS.

Thomas Mears Werge is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2023 and research/prize committee member. Copenhagen clinical-medicine professor and biological-psychiatry research chief, with psychiatric genetics/epidemiology and international programme experience.

JetZero is a US aerospace company developing the Z4, a blended-wing-body commercial aircraft designed for roughly 250 passengers and routes up to 5,000 nautical miles. Its all-wing structure is intended to reduce aerodynamic drag and fuel use compared with conventional tube-and-wing aircraft; the company targets up to 50% lower fuel burn rather than claiming a demonstrated in-service result. It is building the full-scale Jet1 demonstrator with Scaled Composites and US Air Force support, targeting a first flight in late 2027 and commercial Z4 service in the early 2030s. The program also has defense applications and is developing manufacturing facilities in Greensboro, North Carolina.

An aviation executive with prior aircraft and engine industry leadership; listed on JetZero’s advisory board.

Leads the commercial Z4 program and certification, combining aircraft systems experience, pilot qualifications and aerospace engineering training.

Advises on business management, drawing on aerospace operations, government contracts and aircraft-company leadership experience.

A blended-wing-body co-inventor and aircraft advanced-concepts specialist with experience at McDonnell Douglas and Boeing.

An aviation executive who previously led Learjet, Galaxy Aerospace and Aerion, and served in the US Air Force.

A former president of Bombardier Business Aircraft and Gulfstream Aerospace experienced in bringing business jets into service.

Oversees JetZero’s Long Beach campus, including facilities, security and employee wellness, following roles in automotive and technology startups.

An aerospace engineer and commercial aviation executive with experience at Embraer, Douglas Aircraft and Boeing.

Daniel Green Blok Marques is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Leads workplace innovation and campus experience across headquarters and manufacturing facilities, with a background in industrial design and corporate environments.

An aviation and travel investor, Volaris co-founder and DiamondStream Partners co-founder, with earlier consulting and operating experience.

Leads the full-scale demonstrator program and previously served as a Navy pilot, test pilot and commander of Naval Air Systems Command.

An aerospace structures specialist and former Gulfstream executive and chief scientist, with experience in aircraft static analysis and fatigue.

An investor and creative executive formerly CEO of Activision, with advisory experience in technology and aerospace companies.

Leads business operations, with a background in systems engineering and program management at Boeing, Gulfstream and Naval Air Systems Command.

An engineering executive experienced in aircraft development, testing, manufacturing and support at Rolls-Royce, Bombardier and Airbus.

A flight-controls engineer experienced in fly-by-wire systems and avionics development at Thales and on Gulfstream aircraft programs.

An aircraft cabin and product designer experienced at Zodiac Aerospace, BMW Designworks and Safran, and co-founder of Applied Mobility Partners.

A people leader with accounting and business analytics training and prior financial-management experience at ICON Aircraft.

An engineer experienced in propulsion integration, aircraft systems and flight operations, previously at GE Aviation and Virgin Orbit.

A Stanford aerodynamics researcher and founder of ZeeAero, with experience in early blended-wing-body research and aircraft design.

B Capital’s General Partner and Global Head of Energy, with investment and operating experience in energy and industrial technology. Current primary B Capital biography reviewed October8,2026: With nearly 25 years of investment, entrepreneurship and corporate experience across energy and technology, Jeff most recently served as a Managing Director at Temasek, where he led the US-based investment team focused on energy and industrial growth investments deploying >$1b of capital. Previously, he ran a boutique advisory business focused on scaling sustainable businesses. He also co-founded and was on the Board of Xpansiv, the world’s leading provider of market infrastructure for environmental commodities. Earlier in his career, Jeff worked in innovation business development at ABB, leading growth initiatives for new sustainable products and services, and held leadership, business development and technical roles at Better Place, Vendavo and Intel Corporation. Jeff earned a BS in Industrial Engineering from University of Florida and an MS in Engineering Systems from the Massachusetts Institute of Technology.

Leads company communications, with prior commercial aviation communications roles at RTX, Qatar Airways, JetBlue, TWA and Delta.

Leads security, with prior intelligence and security operations experience at the World Bank and major companies.

An aerodynamics specialist and former Boeing Phantom Works chief aerodynamicist who developed aircraft efficiency improvements.

Works across aerospace policy and government affairs, with experience in Boeing advocacy, consulting and US government trade and national-security functions.

Leads structures engineering, with experience developing large composite aircraft structures across commercial and defense platforms.

A graphic and product designer with experience in branding, software and design systems at Atari, Acquia and BETA Technologies.

An aerospace supply-chain leader with prior roles on Space Shuttle, Gulfstream, HondaJet, HAECO and Northrop Grumman programs.

An aircraft designer and blended-wing-body pioneer who co-founded JetZero. The company’s April 2023 release identified him as CTO; that executive capacity is not confirmed by the current roster.

An aviation executive with experience at Pratt & Whitney and aerospace industry organizations; listed on JetZero’s advisory board.

An aerospace customer-engagement executive with experience in systems engineering, aftermarket sales and connected-aircraft technology at Gulfstream.

Leads market development and sales engineering, drawing on aerospace research and advisory experience at Frost & Sullivan, G2 Solutions and AIR.

An aviation executive experienced in airline leadership and fleet advisory work; listed on JetZero’s advisory board.

An aerospace and defense executive who formerly led Spirit AeroSystems, held senior Boeing roles and served as Acting US Secretary of Defense.

An aircraft design and development executive formerly at McDonnell Douglas and Gulfstream, with experience on the MD-80, MD-90 and Gulfstream programs.

An aerospace engineer, former Air Force pilot and aviation regulator appointed as a commercialization advisor in an April 2025 company announcement. Current membership is not confirmed in the live roster.

An attorney with experience in finance, commodities and global commercial legal operations, previously at Mastercard.

An aircraft program executive known for leading development, certification and delivery of the CSeries/A220; also advises JetZero technically and serves on its board.

An aerospace propulsion leader with experience in Boeing commercial and defense programs, advanced concepts and defense strategy.

A corporate executive experienced in scaling technology, defense, autonomous systems, consumer electronics and platform companies through growth and financing.

An aerospace product and design leader with experience in engineering, operations, sales and cabin-product innovation at Zodiac Aerospace and Safran.

An aviation finance executive with experience across aircraft manufacturing, airlines, leasing and capital providers, including Airbus, AerCap and Wisk.

An aviation support and aftermarket executive with experience in aircraft leasing, maintenance, manufacturing and technical services.

A former FAA administrator, Air Force pilot and Delta executive advising JetZero on aviation matters.

Previously worked in automotive and technology startups and was COO of BETA Technologies; co-founded JetZero with aircraft designer Mark Page.

An aircraft sales and leasing executive and founder of JetStar Partners, with experience in asset management and aviation policy.

A supply chain manager at JetZero, publicly identified in the company’s team directory.

Cæcilie Hougaard Pedersen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Charlotte Vinther Bertelsen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Christian Frost is published by Innovation Fund Denmark as Senior Analytics Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Cecilie Uldall Duch is published by Innovation Fund Denmark as Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Cecilie Würtz Krog is published by Innovation Fund Denmark as Legal Officer (parental leave). This affiliation is listed in the institution’s October2026 public employee directory; the institution explicitly marks the person as on parental leave. the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Esmeralda Lewis is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Michael Kjær is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2016, research/prize committee member and clinical sports-medicine professor/chief physician affiliated with Bispebjerg and Copenhagen. Musculoskeletal/metabolic research and research-management experience.

Morten Hummelmose is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2025 and investment-committee member. Copenhagen economics and London finance masters, with private-equity/investment leadership background at EQT.

Cecilie Brøkner is published by Innovation Fund Denmark as Chief Executive Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Cecilie Tordrup Andersen is published by Innovation Fund Denmark as Executive Assistant. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Isabelle Zenklusen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Lars Holmqvist is listed by the Lundbeck Foundation as Deputy Chair. Foundation board member elected2015 and Deputy Chair. International medtech/pharma leadership and commercial/finance experience; published investment-committee membership.

Søren Skou is listed by the Lundbeck Foundation as Chair. Foundation board member elected2024 and current Chair, with investment-committee leadership. Copenhagen business/economics degree and IMD MBA; international corporate, infrastructure and governance experience.

Anne Kathrine Nissen Pedersen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Caroline Sofie Gundestrup is published by Innovation Fund Denmark as Program Officer, International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Cecilia Elise Kaas Rutherford is published by Innovation Fund Denmark as Student Assistant. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Karina Jeppesen Morgen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Camilla Trothe Mygind is published by Innovation Fund Denmark as Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Linda Lomholt Petersen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Lone Michelsen is listed by the Lundbeck Foundation as Service Coordinator. Current named Service Coordinator. Own detailed academic/career biography is unpublished.

Frederik Madsen is listed by the Lundbeck Foundation as Manager, Sustainability. Former PwC finance/sustainability consultant and Terma performance-management professional. Aarhus business qualification; focuses on sustainability strategy/reporting.

Kenneth Lütken Rode is listed by the Lundbeck Foundation as Office Manager. Administrative/service professional with earlier finance, operations, marketing and HR work, including SAS cabin-service experience.

Rasmus Thomsen is listed by the Lundbeck Foundation as Head of Sustainability and Strategy. Former Danish Export and Investment Fund strategy leader, Danish Finance Ministry professional and Brussels diplomat. Copenhagen political-science MSc and London School of Economics masters; works across sustainability and investment strategy.

Børge Lindberg is published by Innovation Fund Denmark as Senior Program Officer, Grand Solutions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Trine Juul Wengel is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Bodil Therese Lundstrøm Bang is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Anders Ulv Mandsholm is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Asger Narud is published by Innovation Fund Denmark as Head of International & Missions. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Bo Billeskov Grünberger is published by Innovation Fund Denmark as Communication Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Jesper Friese is listed by the Lundbeck Foundation as IT Manager. Joined January2019 after fifteen years at ITR Data in system administration/development. TEC Ballerup and Niels Brock training; manages daily IT operations.

Max Siller is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Helle Rejkjær is listed by the Lundbeck Foundation as Accountant. Current Finance Accountant. Own detailed academic/career biography is unpublished.

Arne Nielsen Skov is published by Innovation Fund Denmark as Senior Finance Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Lotte Halse is listed by the Lundbeck Foundation as Investment Controller. Joined Lundbeckfond Invest finance2012 after asset-management support and administration leadership at Gudme Raaschou, Straumur and ATRIUM.

Sune Nordby Madsen is listed by the Lundbeck Foundation as Controller. Current Finance Controller. Own detailed academic/career biography is unpublished.

Anne-Marie Larsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Anne-Mette Iversen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Anne Sofie Bramsen Dahlmann is published by Innovation Fund Denmark as Relations Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Steen Saaby is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Alva Hebe Sørensen is published by Innovation Fund Denmark as Student Assistant, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Andrea Bøcker is published by Innovation Fund Denmark as HR Officer. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Joanna Krzynowek is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Olufunke Adebiyi is listed by the Lundbeck Foundation as Head of Tax. Joined2024 as Head of Tax after PwC Nigeria/Denmark and VKR Holding roles. ACCA fellow with tax/compliance experience; published short name Funke.

Jürgen Brem is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Jurij Radzevic is listed by the Lundbeck Foundation as Digital Marketing Specialist. Joined September2025 after technology-startup marketing work. Southern Denmark marketing/globalisation/communication masters and international study/work experience.

Søren Christiansen is listed by the Lundbeck Foundation as Senior Vice President, Finance. State-authorised public accountant and former EY/KPMG audit/advisory partner; leads finance, accounting, tax and IT.

Victor Ortega is listed by the Lundbeck Foundation as Political Consultant. Current Political Consultant in Public Affairs. Own detailed academic/career biography is unpublished.

Alberte Kring Korsgaard is published by Innovation Fund Denmark as Student Assistant, Økonomi. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Alexander Sienczak Knudsen is published by Innovation Fund Denmark as Program Officer, Start Up & SMV. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Camilla Tvede Schytz is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Aila Lonka is published by Innovation Fund Denmark as Head of Finance. This affiliation is listed in the institution’s October2026 public employee directory; the directory provides this professional position and an original named portrait, without a substantive prior-career biography or employment commencement date.

Innovation Fund Denmark, legally Danmarks Innovationsfond and historically branded Innovationsfonden, is Denmark's public research and innovation funding institution, CVR 29035695. Its mission is to translate research and knowledge into businesses, technologies and societal benefit rather than earn a financial return. Its current website explicitly identifies artificial intelligence, quantum technology, critical digital technologies, biotechnology, life sciences and health among its areas of support. It has offices in Aarhus and Copenhagen. The institution began operating in 2014. Its annual report accounts for Danish Finance Act appropriations under the Ministry of Higher Education and Science. Its legal basis is the Act on Danmarks Innovationsfond, including the consolidated Act no.156 of February13,2025. This is an institutional public grant provider, distinct from commercial venture capital funds and Innovation Fund Europe. Annual appropriations, programme envelopes and outstanding grant commitments are not external LP fund closes or fresh company equity. Its public programmes include Innobooster for knowledge-based SME development, Innoexplorer for research commercialization, Innofounder for entrepreneurs, Industrial Researcher, Grand Solutions partnerships, international research collaborations and mission-driven Innomissions. Published company and project relationships must retain their actual programme and funding form. Grant support does not imply share ownership, a clinical approval or a personal investment by a board member. The current published executive leadership is CEO Cecilie Brøkner, Chief Program Officer Søren Asp Mikkelsen and Chief Financial Officer Michael Friis Lindinger. The full public employee directory is recorded separately from external governance and expert panels. Anders Eldrup chairs the board and Philipp Schröder is vice chair. The September11,2026 official appointment announcement adds Jes Broeng and Ingrid Sofie Harbo and renews Philipp's appointment through June2029. Mette Glavind's term is extended through June2027. Thomas Bech Hansen's announced appointment begins July1,2027; he is not represented as a current director in October2026. The authoritative current Danish board directory includes Peter Holme Jensen and excludes Christian Ketels and Sine Reker Hadrup. The latter two are retained as explicitly historical March2026 annual-report affiliations, with unknown exact departure dates. The English machine translation retains a stale roster and is not used to override the Danish directory. Peter, Morten Novak Bro and Mette Glavind also serve on the published Programme Oversight committee. The September2026 website launch adopted the full statutory name and danmarksinnovationsfond.dk domain without changing the institution's legal identity. The stored authentic logo is the official historical wordmark extracted from the March2026 annual report; the new brand's linked official asset library currently returns no public access, so the replacement logo remains a documented gap. Generic placeholder board images are not authentic portraits. NMD Pharma announced receipt of a EUR629,000 grant on November30,2020 for discovery and development of medicines for neuromuscular disease. A later DKK4.7million reference concerns that same award rather than a second grant or equity financing. Other published relevant project recipients include gMendel's AI-based genetic diagnostics and Chromaviso's circadian lighting research. Their project budgets are distinguished from the institution's own grant contribution; exact additional company links require separately verified recipient profiles and award evidence.

Marlene May Vestergaard is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Gitte Grove Stig is listed by the Lundbeck Foundation as Senior Manager, Outreach and Partnerships. Joined April1,2018 with earlier pharmaceutical medical-marketing and event/partnership experience. Coordinates outreach and university relationships.

Kasper Riis is listed by the Lundbeck Foundation as Head of Communications. Joined January2024 after Nets, Tryg and life-science communications roles involving Nycomed, Novo Nordisk Engineering and Lundbeck. Roskilde communications/geography BA and journalism training.

Margrethe Nabe-Nielsen is listed by the Lundbeck Foundation as Director of Public Affairs & Signature Projects. Joined August2020 with earlier Danish Ministry of Education, volunteer-council and scout-association public-affairs experience. Copenhagen political-science masters.

Maria Nymark Jensen is listed by the Lundbeck Foundation as HR Consultant. Joined2025 after Copenhagen Business Academy HR partnership and ATP HR-specialist work; supports people processes, wellbeing and events.

Laurane Mackels is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Founder of iGnosis Capital and former CEO & Chairman of Inmar Intelligence, which he led through three PE recapitalizations and 15+ acquisitions. Earlier, CFO of UPS Supply Chain Solutions and EVP & CFO at Domino’s.

Karen Wibe Enevoldsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Outpost Technologies Corporation develops reusable cargo-return vehicles and logistics infrastructure for orbital manufacturing, research and government missions. Its CarryAll platform combines modular payload capacity, controlled reentry and precision landing, with configurations for return from orbit, stratospheric deployment and aircraft delivery. Outpost Space Factories supplies orbital production infrastructure and return services for customers developing materials, pharmaceuticals and other products in microgravity. Its StarFiber optical-fiber product uses microgravity manufacturing for communications, sensing, quantum technology and AI infrastructure applications.

Christina Polyzogopoulou is listed by the Lundbeck Foundation as Student Analyst. Joined April2025. Aristotle University Thessaloniki biology degree, multimedia/web-development study and current IT University Copenhagen software-design masters; supports Neurotorium technical and creative work.

Maika Pedersen is listed by the Lundbeck Foundation as Student Analyst. Joined January2026. King’s College London neuroscience/psychology degree and current Copenhagen Business School digital-business masters study; supports Brain Prize programmes.

Mette Eistrøm Krüger is listed by the Lundbeck Foundation as Senior Vice President, People & Corporate Affairs. Joined March2025 following Telenor Nordic and Danish people/corporate-affairs leadership. Aalborg business-law qualification; leads HR, communications and public affairs.

Terese Vibe Boye is listed by the Lundbeck Foundation as Student Analyst. Joined September2025 alongside Copenhagen public-health masters study. Earlier innovation/medical-affairs and Danish Embassy London life-science work; supports Neurotorium content and communications.

Hang Nguyen Nielsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Lone Lund is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Michael Dyrgaard Lundov is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Anne Sofie Danekilde is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Alok Singh is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Sidsel Dan Hull is listed by the Lundbeck Foundation as Grant Manager. Joined September2026 after an earlier foundation student-analyst term2018–2022. Copenhagen public-health masters and environmental-epidemiology PhD; administers applications and reporting.

Ulla Vig Nissen is listed by the Lundbeck Foundation as Senior Scientific Programme Manager. Joined August2026 from Novo Nordisk Foundation. Earlier neuroscience research at Oslo/Karolinska/Copenhagen, spinal-cord rehabilitation work, SSI/DTU grant support and medical-device project management. Copenhagen biology MSc and Oslo neuroscience Dr.philos.

Louise Bruun is listed by the Lundbeck Foundation as Executive Assistant. Joined March1,2018 after executive-assistant roles involving ATP, Danish ministries and the Royal Court. Supports science leadership, Brain Prize and Neurotorium administration.

Niels Hoffmann Haahr is listed by the Lundbeck Foundation as Grant Manager. Joined January2025 after health-science administration and nine years of Danish Patient Compensation casework. Aarhus ethnography/social-anthropology masters with medical-anthropology focus; administers grants/data through LANAS.

Maja B. Nielsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Cecilia Sparr Eskilsson is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Karen Hue is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Bryn Farnsworth von Cederwald is listed by the Lundbeck Foundation as Scientific Programme Manager, Neurotorium. Joined April2024 after aging/dementia research at Nottingham, Uppsala and Umeå and science-communication work in behavioural-research software. Sheffield MSc and Uppsala PhD.

Karen Nørby á Rógvu is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Nanna Junker is listed by the Lundbeck Foundation as Senior Scientific Programme Manager, Frontier Grants. Joined January2023 with academic/industrial preclinical and translational project-management experience. Natural-sciences masters and Copenhagen PhD; supports Frontier Grants.

Ceren Akdeniz Vogt is listed by the Lundbeck Foundation as Head of Neurotorium, Outreach and Partnerships. Joined March2023 after medical-science industry roles. Tübingen neural/behavioural-science MSc and Heidelberg psychiatry doctorate; leads Neurotorium scientific content, partnerships and outreach.

Henriette Natorp Tobiesen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Julie Marie Brandt is listed by the Lundbeck Foundation as Senior Scientific Programme Manager. Joined February2024 after outpatient psychiatry, clinical research and Danish Police psychology work. Copenhagen psychology MSc and psychiatry PhD; develops clinical-psychiatry initiatives.

Mette D. E. Jepsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Cecilie Kirkeby Skeby is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Signe Rode Andreasen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Teresa Gidaro is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Anette Høye is listed by the Lundbeck Foundation as Senior Scientific Programme Manager. Joined July2018 after Copenhagen postdoctoral research. Syracuse BSc and Copenhagen human-biology MSc/PhD; handles science engagement and investigator-network programmes.

Line Vildbrad Kristensen is listed by the Lundbeck Foundation as Senior Scientific Programme Manager. Foundation employee2017–2022, BioInnovation Institute Principal2023, returned January2024. Aarhus medicinal-chemistry masters and Copenhagen/Lundbeck industrial PhD; supports brain-health and open/Frontier grant programmes.

Paul Kristjansen is listed by the Lundbeck Foundation as Senior Scientific Director, Frontier Grants. Joined August2022 after Lundbeck licensing/M&A and research/clinical-development roles involving Copenhagen, Harvard and Novo Nordisk. Copenhagen MD/PhD/DMSc; oversees translational Frontier Grants.

Dorthe Bach Toft is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Morten Dahl Sørensen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Peter Thostrup is listed by the Lundbeck Foundation as Scientific Programme Director, Open Programmes. Joined June2021 following Carlsberg Foundation secretariat leadership2016–2021 and earlier Aarhus/McGill research. Aarhus physics MSc/PhD, with neurobiology postdoctoral work; manages open-competition programmes.

Vera Kiyasova is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Thomas Breuer is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Gustav Brøbecher Thorndahl is listed by the Lundbeck Foundation as Student Analyst. University of Copenhagen law student with earlier law-firm student experience; supports legal work and the management office.

Jan Egebjerg is listed by the Lundbeck Foundation as Senior Vice President, Grants & Prizes, Director of Science. Joined August2019 after CNS research and management at Lundbeck, Janssen and Novo Nordisk, with earlier Aarhus molecular-biology academic affiliation. Aarhus masters/PhD; oversees philanthropic science grants and prizes.

Lars Torup is listed by the Lundbeck Foundation as Scientific Programme Director - Strategic Programmes. Joined March2018 from Novo Nordisk Foundation after sixteen years of Lundbeck neurology/psychiatry drug research. Copenhagen biochemistry MSc and neuropharmacology PhD; develops neuroscience initiatives.

Martin Meyer is listed by the Lundbeck Foundation as Scientific Programme Director - The Brain Prize and Neurotorium. Joined2020 after King’s College London neuroscience group leadership and Stanford postdoctoral research. University College London biology degree and cell/developmental-biology PhD; oversees Brain Prize and Neurotorium.

Beyond Medicine, Inc. develops and commercialises RebelCell, a clinic-distributed skincare brand built around its proprietary MitoCyte complex and research into mitochondrial activity in skin ageing and recovery. Its current post-treatment formulations are designed for use after aesthetic procedures including energy-based treatments, microneedling, chemical peels and surgery. The company describes its products as Swiss-made and clinically tested, with intended effects on cellular energy, inflammatory biomarkers and oxidative stress; these are the issuer’s product claims, not assertions of an approved drug or proven treatment for disease. Its official terms identify Beyond Medicine, Inc. as the operator of RebelCell and the partner-clinic sales channel. Kidron Capital lists the company in its portfolio and names Maria Gajda Horowitz as a board member. This is distinct from the South African homeopathy business beyondmedicine.co.za and the Dutch Rebelcell battery manufacturer.

Niels Chr. Felumb is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Beatriz Sevilla-Jensen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Caitlin Cornwall is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Anette Kjær Petersen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Emil Bernekilde Andreasen is listed by the Lundbeck Foundation as Digital AI Consultant. Former IT consultant at Visma Consulting and Twoday. Copenhagen Business School Digital Business masters; supports AI assistants, automation, process design, implementation and training.

Mette Line Braad is listed by the Lundbeck Foundation as General Counsel. Current General Counsel. Own profile does not publish a detailed career or academic biography.

Anette Mullerup Schmidt is listed by the Lundbeck Foundation as Executive Assistant to the CEO. Joined March1,2023 after executive-assistant positions at Ørsted, Rambøll, Maj Invest and Accenture; supports the CEO and foundation board.

Lene Skole is listed by the Lundbeck Foundation as Chief Executive Officer. Foundation CEO since2014. Previously Coloplast CFO2005–2014 and Maersk Company Ltd CFO2000–2005; studied at Copenhagen Business School, London Business School and IMD. Published governance experience spans healthcare, energy and banking.

Jesper Emil Jakobsgaard is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Pernille Bogetofte Thomasen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Stine Krag Brunvold is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Gabrielle Chappell is listed by the Lundbeck Foundation as Associate. Current named BioCapital Associate. Own detailed career and education biography is unpublished; published directory image is a foundation-logo placeholder, not a portrait.

Jette Brandsen Bundgaard is listed by the Lundbeck Foundation as Executive Assistant & Facility Manager. Joined2014 after executive-secretarial work at Bispebjerg Hospital and Danske Bank/Danske Securities. Qualified legal and medical secretary; supports unit administration and partners.

Michael Voldsgaard Clausen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Thomas Skjærlund Grønnebæk is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Jan-Erik Messling is listed by the Lundbeck Foundation as Principal. Former BCG biopharma/medtech consultant with earlier Danish/German cancer and stem-cell research. Cologne biological-sciences MSc and Copenhagen molecular-disease PhD.

Liane Dupont is listed by the Lundbeck Foundation as Principal. Earlier molecular and clinical coronavirus researcher at King’s College London. Copenhagen molecular-biomedicine BSc and Cambridge medical-sciences MRes/PhD; current own board-observer affiliations are separately qualified.

Trine Böenche Sørensen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Katja Krustrup Pedersen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Lilou Marchand was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Matt Suminski was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Nicole Nicolajsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Paolo Joaquim dos Santos was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Robert Law was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Antoine Moreno was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Jacob Falck Hansen is listed by the Lundbeck Foundation as Partner. Former Novo Nordisk corporate-strategy head with fifteen years across pharma strategy and leadership advice. University of Copenhagen biochemistry MSc/PhD and research-publication background. Own biography identifies Vesper Bio CEO and several board/observer affiliations; no personal investment is inferred. Jacob Falck Hansen is currently listed by Vesper Bio as CEO. Previously led Novo Nordisk corporate strategy and holds Copenhagen biochemistry MSc/PhD; appointed Vesper CEO July2025.

Kevin Dalgaard is listed by the Lundbeck Foundation as Senior Principal. Former Novo Nordisk R&D, marketing and business-development professional. University of Copenhagen biochemistry MSc and Max Planck Institute PhD, with published molecular-biology research.

Lars Gredsted is listed by the Lundbeck Foundation as Partner. Earlier AstraZeneca/MedImmune business development, Wellcome Trust life-science investing, Oxford biotechnology and BCG consulting. Copenhagen biochemistry masters, Heidelberg/EMBL PhD and Cambridge MPhil. Current directory says Partner while an older biography paragraph still says Senior Principal; directory controls current title.

Martin Dominguez was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Nisha Marathe is named as Investment Director in South San Francisco in the original Roche2023 presentation. Her self-published professional profile continues to show an RVF affiliation, but she is absent from the current five-person corporate directory. This record preserves the historical publication without guessing a departure or asserting a current title.

Peter Bentsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Anasse Laafou was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Kamilla Løhde Tordrup Dybdahl is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Mohamed Aziz Omri was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Narimane Gassa was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Carole Nuechterlein is named as Head of Roche Venture Fund in its original2023 presentation. The current primary directory names Anja Harmeier as head. This historical leadership record is explicitly qualified; exact departure day is not established.

Jeppe Blichfeldt Winther is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Kirushini Satkunaseelan was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Marianne Gerberg Skals is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Eléa Robert was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Simon Greenwood is a Senior Investment Director in Roche’s current published venture-fund directory. COUR’s own board biography independently names the same RVF role. The original Roche2023 presentation places him in South San Francisco. Company board affiliation does not establish a personal cash investment.

Louise-Amélie Schmitt was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Pauline Migerditichan was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Anna Jul Bjørn is listed by the Lundbeck Foundation as Investment Associate. Former Nordea equity researcher covering Nordic financial institutions. Copenhagen Business School finance/accounting masters.

Per Hajslund Mayo is listed by the Lundbeck Foundation as Associate Director. Joined May1,2021 after Danske Bank equity research and Nykredit M&A advisory in energy/infrastructure. Copenhagen Business School finance/strategic-management masters.

Rasmus Thoning is listed by the Lundbeck Foundation as Investment Associate. Corporate-finance adviser with M&A, capital-structure and valuation experience, including earlier Nrep real-estate transactions. Copenhagen Business School economics/business BA and current finance/accounting masters study.

Steen Walther Jensen is listed by the Lundbeck Foundation as Senior Investment Director. Joined June1,2020 following Danske Bank asset-management and strategy work and earlier Gudme Raaschou/Kaupthing corporate finance. Copenhagen Business School finance/accounting MSc.

Nicholas Kelly is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Dorothee Uriet was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Thomas Queuche is named as RebrAIn’s Quality and Regulatory Affairs Manager in its July2024 FDA submission for OptimMRI v2 and as Data Protection Officer in the company’s published privacy policy. Its own January2025 post also names him in its professional team. Exact current operating title continuity is distinguished from these published dates.

Arkuda Therapeutics, Inc. is a US biotechnology company founded in 2018 by Atlas Venture, Gerhard Koenig and Duane Burnett, historically based in Cambridge and subsequently Watertown, Massachusetts. It developed brain-penetrant small-molecule enhancers of progranulin and lysosomal function for neurodegenerative diseases, initially GRN-related frontotemporal dementia and potentially Alzheimer’s and Parkinson’s disease. ARKD-104 was described in July 2023 as an investigational IND-enabling development candidate; an expected trial start is not proof that clinical trials subsequently began or that the therapy demonstrated efficacy. Arkuda announced a USD44 million Series A in November 2019 and a USD64 million Series B in February 2022. In February 2024 it entered an option and asset purchase agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, involving an undisclosed commercial option payment and a separate equity investment from Johnson & Johnson Innovation–JJDC, Inc. In January 2025 Johnson & Johnson exercised the option to buy Arkuda’s portfolio of lysosomal function enhancers, with an undisclosed upfront payment and potential milestone payments. This was a portfolio asset transaction; the announcement does not establish acquisition of the Arkuda legal company. Its investors classify the holding as exited. Historical leadership and scientific staff are sourced to original archived company biographies and dated announcements, without asserting continued employment after the asset sale. Gerhard Koenig became CEO of Augustine Therapeutics in January 2025; Serena Hung joined Atalanta Therapeutics in May 2024. Arkuda’s former arkudatx.com domain now serves unrelated content and is not listed as a current company website. Current standalone operating status and a replacement official domain are unverified. Its relevance is neuroscience and drug discovery; no AI platform, approved treatment or undisclosed transaction value is inferred.

Antoine d’Humières was named in RebrAIn’s own January2025 public team announcement. This records a dated professional affiliation; an exact operating title and continuing employment in2026 are not independently established.

Gabriella Zöch is Project Manager in Roche’s current published venture-fund team. The original Roche2023 presentation also names her in project management in Basel. Exact tenure dates and further professional biography are not publicly verified.

Nete Huus is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Dana Varinos is publicly named by Cormorant Asset Management as data operations associate. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Garrett McGlory is publicly named by Cormorant Asset Management as finance manager. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

John Coners is publicly named by Cormorant Asset Management as director of investment analytics. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Keaton McKernan is publicly named by Cormorant Asset Management as controller. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Teddy Wan is publicly named by Cormorant Asset Management as deputy general counsel. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

May Health develops the Anavi System, a medical device intended to restore natural ovulation in women with infertility associated with polycystic ovary syndrome (PCOS). The one-time, ultrasound-guided procedure uses radiofrequency energy to ablate targeted ovarian tissue, aiming to reduce ovarian androgen production. It is being evaluated for women who do not respond to, cannot use, or decline first-line ovulation-induction therapies. The system received European CE certification under the EU Medical Device Regulation in October 2025. In the United States it remains investigational: the company is enrolling its randomized REBALANCE pivotal IDE trial to support a future application for FDA marketing authorization. European commercialization is being planned; CE certification does not establish US marketing approval. The company evolved through Sofinnova MD Start, previously operated as Ablacare, and has teams in Paris and Menlo Park.

Anne Bubb is May Health’s vice president, marketing. The company publishes this current affiliation on its own team and board page.

Aruna Akkapeddi is May Health’s vice president, quality assurance/regulatory affairs. The company publishes this current affiliation on its own team and board page.

Bita Sehat is May Health’s director. The company publishes this current affiliation on its own team and board page.

Cindy Domecus is May Health’s chief regulatory advisor. This is an advisory role published on the company’s own current team page.

Colby Holtshouse is May Health’s president, chief executive officer and director. The company publishes this current affiliation on its own team and board page.

Connie Rey is May Health’s vice president, clinical affairs. The company publishes this current affiliation on its own team and board page.

Hugh E. Magen is May Health’s chief technical officer. The company publishes this current affiliation on its own team and board page.

Robert Auerbach is May Health’s board chair. The company publishes this current affiliation on its own team and board page.

Ross W. McQuivey is May Health’s chief medical advisor. This is an advisory role published on the company’s own current team page.

Nikolaj Frederik Kamedula is listed by the Lundbeck Foundation as Senior Investment Director. Joined2019 after Danish Ship Finance, FIH, SEB and Nordea Asset Management roles. Holds economics masters and focuses on listed equities and credit.

Peter Rothausen is listed by the Lundbeck Foundation as Senior Vice President, Financial Investments and Head of Invest. Joined May1,2018 after Danske Capital portfolio leadership and earlier Carnegie/FIH/Danske Bank equity research. Copenhagen Business School finance/accounting MSc.

Poul la Cour is listed by the Lundbeck Foundation as Senior Investment Director. Joined2015 after Novo Nordisk corporate strategy and FIH/Carnegie research roles. Copenhagen Business School finance/accounting MSc; co-manages financial investments.

Rasmus Linde Larsen is listed by the Lundbeck Foundation as Associate. Earlier PwC financial due-diligence/M&A work. Copenhagen Business School finance/accounting masters; supports healthcare ownership analysis and new strategic investments.

CardioRenal Systems is a medical-device company developing automated fluid-management technology to protect kidney function during high-risk hospital procedures. Its console measures urine output and adjusts physician-prescribed intravenous hydration to replace fluid losses, using disposable infusion and urine-collection sets. The technology is branded RenalPro in the United States and RenalGuard internationally, with development focused on preventing acute kidney injury associated with cardiac surgery and other cardiovascular interventions. CardioRenal Systems, Inc., based in Milford, Massachusetts, is identified in the current operator manual as the manufacturer and parent of RenalGuard Solutions, Inc. The company reports that RenalGuard is CE marked for fluid-balance management outside the United States. RenalPro remains investigational in the United States; the company’s July2026 announcement reports FDA permission to conduct a pivotal cardiac-surgery trial, rather than marketing authorization.

Anders Findsen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Avi Wise directs business operations at CardioRenal Systems. His published experience includes healthcare innovation analysis at Imagine Bio and business-development and operations projects; he studied biology at Northland College.

Dan Engelman is a member of CardioRenal Systems’ Scientific Advisory Board. The issuer identifies him as a cardiothoracic surgeon and medical director at Baystate Medical Center and head of the Enhanced Recovery After Surgery Society.

Ethan Benovitz is chairman of CardioRenal Systems. His published biography describes more than twenty-five years investing in healthcare and technology and an earlier corporate-law career after Harvard Law School.

Heyman Luckraz leads medical affairs at CardioRenal Systems. He is a cardiothoracic surgeon with UK and UAE clinical experience and involvement in the RenalGuard cardiac-surgery validation study.

Ilya Budik leads CardioRenal Systems as CEO. His published experience includes healthcare product and business strategy at Imagine Bio and leadership of NeuroQuest; he studied finance and biochemistry at Miami University.

Jacob Raphael is a member of CardioRenal Systems’ Scientific Advisory Board. The issuer identifies him as an anesthesiologist at Thomas Jefferson University Hospital researching perioperative care and prevention of acute kidney injury after cardiac surgery.

Janice Hogan is a regulatory adviser to CardioRenal Systems and a partner at Hogan Lovells. The issuer biography describes experience guiding medical devices through FDA review and engineering and law degrees from MIT and Georgetown.

Laura Dern is published as president in CardioRenal Systems’ management directory. The company does not publish a career biography for this person.

Richard Solomon advises CardioRenal Systems on its Scientific Advisory Board. The issuer identifies him as a University of Vermont nephrology professor with acute-kidney-injury clinical-trial and biomarker research experience.

Robin Luper leads international sales at CardioRenal Systems. His issuer biography describes medical-device sales and international distribution experience and the launch and growth of Acist sales.

Shmulik Adler leads clinical and regulatory affairs at CardioRenal Systems. His published medtech experience includes clinical trials and regulatory work at Nucleix, Oridian and Brainsway.

Todd Rosengart is a member of CardioRenal Systems’ Scientific Advisory Board. His issuer biography identifies him as a surgical chair at Baylor College of Medicine and Texas Heart Institute with cardiac-surgery clinical research experience.

Tzvi Stern is CardioRenal Systems’ chief financial officer. His biography describes finance work in technology and biotechnology, transactions at Regenocell Labs and Magnifire, and earlier accounting at KPMG.

Victor Schmelzer is a member of CardioRenal Systems’ Scientific Advisory Board. The company identifies him as a cardiovascular surgeon at St. Elizabeth Healthcare with experience in complex heart surgery.

William Denman, published with the nickname Pepper, advises CardioRenal Systems on medicine and industry. His biography lists previous chief medical officer roles at Covidien, GE Healthcare and Cheetah Medical and anesthesiology at Massachusetts General Hospital.

Caleb Tripp is chief financial officer and chief operating officer of Cormorant Asset Management. Its current official roster publishes his named portrait; the May 2026 SEC filing identifies the same Caleb Jonathan Tripp and dates the CFO/COO role to August 2020. The role concerns manager operations and financial oversight.

Jay Riccio is publicly named by Cormorant Asset Management as head trader. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Neb Obradovic is general counsel and chief compliance officer of Cormorant Asset Management. The current official roster and genuine named portrait match the May 2026 SEC legal name Nebojsa Obradovic, with the compliance/general-counsel role dated January 2016. The shortened professional name and legal name refer to the same published manager role.

Sarah Roxe is publicly named by Cormorant Asset Management as director of investor relations. The current official manager directory publishes an authentic named portrait and identifies this specific professional affiliation. Cormorant is a biotechnology and healthcare adviser investing across private and public markets. Further career history and a precise appointment date are not supplied by this roster.

Bihua Chen founded Cormorant Asset Management in 2013 and is its current chief executive officer and chief investment officer. The May 2026 SEC filing identifies her as managing member and CEO since March 2013. She oversees a biotechnology and healthcare strategy spanning public and private companies. Fund-control and voting authority are institutional legal roles, not automatically personal investment checks. A 2026 issuer proxy records a Fudan genetics and genetic-engineering degree, a Cornell molecular-biology master’s and a Wharton MBA, alongside earlier healthcare analyst and portfolio-management roles.

Jean Régis is listed on RebrAIn’s published scientific/medical advisory board, with affiliation APHM, Marseille.

Shayan Moosa is listed on RebrAIn’s published scientific/medical advisory board, with affiliation University of Virginia, Charlottesville.

Dorte Olsson is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Charles Munyon is listed on RebrAIn’s published scientific/medical advisory board, with affiliation Charlotte Novant Health.

Michael J. Kinsman is listed on RebrAIn’s published scientific/medical advisory board, with affiliation University of Kansas Hospital, Kansas City.

Joohi Jimenez-Shahed is listed on RebrAIn’s published scientific/medical advisory board, with affiliation Mount Sinai, New York.

Founder, president, CEO and director of Ascendis Pharma, with earlier leadership at LifeCycle Pharma, Maxygen and ProFound Pharma and protein-discovery experience at Novo Nordisk. His university training is in biochemistry at Odense. Aarhus University’s2015 NeuronIcon closure account identifies him among its founders; that corporate attribution is historical and does not establish a personal funding ticket.

Jeanette Jeppesen Morgen is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

Anna Emilie Møller Koefoed is listed by the Lundbeck Foundation as Associate. Joined2020; focuses on financial and strategic analysis of healthcare ownerships. Copenhagen Business School finance/accounting qualification. Own current biography qualifies maternity leave.

Rasmus Giese is listed by the Lundbeck Foundation as Associate Director. Earlier ABG Sundal Collier investment-banking/M&A work and CS Capital private-equity experience. Copenhagen Business School finance/accounting masters.

Arne Due-Hansen is listed by the Lundbeck Foundation as Senior Vice President, Strategic Ownerships. Responsible for strategic investments fromSeptember2022. Earlier Alfred Berg analyst/corporate-finance work, SEB investment-banking leadership1997–2013 and Danske Bank strategic M&A advisory from2014. Copenhagen Business School finance/accounting masters.

Lain Hermes González is listed on RebrAIn’s published scientific/medical advisory board, with affiliation Clínica Universidad de Navarra, Spain.

Louise Lind Ladegaard is listed by the Lundbeck Foundation as Senior Director. Earlier Danske Bank corporate finance and ISS M&A/transformation work; holds University of Copenhagen economics masters.

Rees Cosgrove is listed on RebrAIn’s published scientific/medical advisory board, with affiliation Brigham and Women’s Hospital, Boston.

Max Delbrück Center scientist leading Molecular Cardiovascular Research, studying intracellular sorting receptors, metabolism and Alzheimer’s disease. His training includes biology/biochemistry in Munich and postdoctoral research at UT Southwestern. Capnova identifies his research as a foundation of NeuronIcon; the International Society of Nephrology’s2011 biography explicitly names him the company’s chief scientific officer. These corporate capacities are historical, not current employment at a closed company.

Ausaf A. Bari is listed on RebrAIn’s published scientific/medical advisory board, with affiliation UCLA Brain Research Institute, Los Angeles.

Vibeke Uhre is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

RebrAIn CEO appointed in the March18,2024 financing announcement, formerly Theraclion CEO with earlier leadership at GE Healthcare. Current French registry identifies him as statutory Président de SAS, distinct from the company directory’s board-president title for Emmanuel Cuny.

Aarhus University biomedicine professor and PROMEMO research leader studying neuronal communication, memory and receptor biology relevant to psychiatric disorders. Contemporary university sources identify his2004 co-founding of NeuronIcon, and the university’s2015 closure notice identifies him as its former leader. His academic laboratory is distinct from the closed company. Anders Nykjær is currently listed by Vesper Bio as FOUNDER AND CSO. Scientific founder and chief scientific officer, researching sortilin and neuronal receptor biology; Aarhus academic biography and existing external roles preserved.

Inria researcher in applied mathematics and RebrAIn co-founder. Its current directory identifies him as CSO and CTO and reports 100 publications in mathematical inverse problems; the French registry separately lists him as Directeur Général.

Professor of neurosurgery at Bordeaux University Hospital and co-founder of RebrAIn. Its current company directory identifies him as Chief Medical Officer and board president; the French legal registry separately lists him as Directeur Général.

Tina Klitte Holmstrøm Lohmann is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

NeuronIcon ApS was a Danish neuroscience biotechnology company built on Anders Nykjær and Thomas Willnow’s research into neuronal receptor signaling and cell survival. Capnova’s own portfolio history and Nykjær’s contemporary university biography place its founding in 2004 and confirm initial risk-capital investment and advisory support by the Capnova predecessor platform. Its research sought therapeutic approaches to neurodegenerative disease and damage after stroke; these are historical research aims, not proof of an approved product or clinical efficacy. In 2009 its technology was sold to Lundbeck and Capnova exited, while the company continued independently in collaboration with academic laboratories. This technology transfer is not modeled as a whole-company acquisition or new equity financing. Aarhus University’s August17,2015 closure announcement says the company wound down after its scientific goals were achieved, names Nykjær as former leader and adds Jan Møller Mikkelsen among its founders. The same article contains a conflicting 2007 founding year and loose acquisition terminology; the more specific investor history and contemporary 2005 university evidence support the 2004 founding and technology-sale scope. Public CVR mirrors identify NEURONICON ApS, CVR26988179, as dissolved after voluntary liquidation, but the official registry could not be retrieved and its exact May2016 legal dissolution day is not asserted as primary verified. Only historical founder/leadership roles are recorded; no current company operating team is claimed. An authentic company logo or surviving company website has not been found; the investor’s brain illustration is editorial art and is not used as a brand image.

Martin Gruwier Broch-Lips is a publicly named team member of NMD Pharma, a Danish clinical-stage company researching skeletal-muscle and neuromuscular therapies. The current own team directory verifies the affiliation and original name-bound portrait; precise job function, education and prior employment are not published there and are not invented.

RebrAIn is a French medical-software company developing supervised AI-based, patient-specific MRI processing and brain-targeting tools for functional neurosurgery. Its legal issuer is Rebrain SAS, SIREN892511866, active since January1,2021 according to the French government register; its US operating affiliate Rebrain US Corp is identified separately on the same corporate website. Neurosurgeon Emmanuel Cuny and Inria applied-mathematics researcher Nejib Zemzemi co-founded the University Hospital of Bordeaux/Inria spin-off following academic research. Its OptimMRI software processes preoperative DICOM MRI images and helps qualified clinicians visualize and localize anatomical structures, including STN/VIM, alongside other clinical methods for neurosurgical planning. FDA records confirm ClassII 510(k) clearance K230150 on July21,2023 and OptimMRI(v2) K242054 on August12,2024; these are software device clearances, not drug approvals, autonomous treatment authorization or independent proof of clinical benefit. The company also reports European CE marking, with an independently retrieved CE certificate not available in this audit. Its current public directory identifies David Caumartin as CEO, Emmanuel Cuny as CMO/board president and Nejib Zemzemi as CSO/CTO, a strategic board and nine scientific/medical advisers. The statutory register separately identifies David Caumartin as Président de SAS and Cuny/Zemzemi as Directeurs Généraux. Additional people in its January2025 team announcement are recorded as dated affiliations where current operating titles cannot be confirmed. A completed EUR3.7M seed financing announced March18,2024 was led by Karista, joined by NACO and unnamed existing investors. Karista’s portfolio year2023 is not treated as a second priced cash event. Regional/EU programme support is reported without an invented amount or paid-cash grant; a171K technology-transfer maturation budget is not assumed paid to this legal company. Executive-career logos are not treated as investors.

M Capital Partners, marketed as M Capital and historically Midi Capital, is an independent French regulated investment manager, SIREN443003504, authorised by the AMF under GP02-028 on October29,2002. It operates venture-capital, growth and transmission private-equity, private-debt, sustainable-finance and property strategies from Toulouse, Paris, Bordeaux and the Côte d’Azur. Its technology strategies support health, artificial intelligence, industrial digitalisation, robotics, space and environmental innovation. The current public directory identifies45 human professionals; the published pet and recruitment cards are excluded. Since September2022 the separate regional investment company Nouvelle-Aquitaine Co-Investissement (NACO) has appointed M Capital to advise its deployment. NACO is owned by Région Nouvelle-Aquitaine and remains the actual buyer where issuer releases name NACO; the advisory manager and vehicle are not duplicated as two checks. The publicly identified11-person NACO deployment team is shared with this manager and its roles are qualified accordingly. Published2026 reporting documents numerous distinct FIP, FCPI, FCPR, FPCI, holding and SLP vehicles. AUM, share capital, remaining deployment capacity, public programme allocations and fundraising targets are distinguished from completed fund closings. Published fund structures are retained with unknown completed close amounts/dates where the reviewed primary documents do not establish them. Current relevant portfolio examples include RebrAIn through NACO and autonomous agricultural robotics company Naïo through FOSTER.

NACO is Nouvelle-Aquitaine Co-Investissement, a separate French single-shareholder regional investment company (SASU), SIREN824626675 and LEI969500WYDW8OHY35DX25. Legally incorporated in December2016 and launched in2017, it is financed and owned by Région Nouvelle-Aquitaine. It makes evergreen pari-passu equity and quasi-equity co-investments alongside private investors in regional startups and SMEs, from early venture through growth, transformation and business transmission. It supports technological and industrial innovation, healthcare and regional social/environmental transitions; its actual neuroscience investment in precision-neurosurgery company RebrAIn is explicitly identified in the March18,2024 financing announcement. M Capital Partners has advised deployment since September2022; the11 named deployment professionals on NACO’s current site are qualified as shared M Capital staff rather than assumed legal-vehicle employees. NACO’s president Jean-Pierre Renaudin is separately documented in its June18,2025 statement. The current site describes a EUR102M programme envelope, while the dated2025 statement calls95M assets under management; neither is imported as an LP fund close or actual portfolio ticket. Historic corporate capital increases and REACT-EU repayable advances are distinct from LP fund subscriptions and individual company equity allocations. Headquarters is24rueVitalCarles, Bordeaux. Its legal identity and investment relationships are kept separate from the regulated advisory manager and unrelated similarly named organisations.

Adrien Raphet joined M Capital in 2021 to develop public-client financing for Fonds Tourisme Occitanie. His earlier banking experience includes Dexia, Caisse d’Épargne Midi-Pyrénées and La Banque Postale.

Aïcha Helal is publicly listed by M Capital as Chargée de Relations Partenaires Clients. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Alexandra Begue is publicly listed by M Capital as Responsable de Programmes Immobiliers. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Amélie Guelff-Mariotti joined M Capital in 2020 in compliance and internal control and now manages sustainable finance. She holds a postgraduate business-law qualification and has prior legal-analysis and legal-services experience.

Anaïs Custodio manages partner relationships and client experience at M Capital. Her published background includes business development and six years supporting property-development activities at Théseis.

Arnaud Aldegheri joined M Capital’s real-estate investment team in 2021 as a financial analyst. He studied management and finance at Toulouse Business School, with earlier experience in Barcelona financial analysis and Paris property-data research at Rock-n-data.io.

Benoît Thiedey joined M Capital in September 2025 as venture investment director, supporting NACO portfolio deployment and Welcome Entrepreneurs. An investor since 2006, he previously worked at Naxicap and Eiffel Investment Group, built Alliance Entreprendre’s venture team from 2017, and joined Seventure Partners in 2022. He holds a Lyon II master’s degree in business valuation and financial engineering.

Bertrand Casteran is publicly listed by M Capital as Directeur Commercial. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Boris Michel is publicly listed by M Capital as Directeur Commercial. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Chaïma El Alaoui El Ismaili is publicly listed by M Capital as Chargée Conformité. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Christophe Maurel joined M Capital in 2018 and leads Welcome. His published work includes developing entrepreneurial investment platforms and the Good Property and Buildr crowdfunding initiatives.

Chrystelle Mouligné joined M Capital in 2020 and handles accounting for M Capital Partners and M&Co Conseils. Her published earlier experience includes Scamp TP, Roldan and Merch & Cie.

Clément Bauguil joined M Capital in 2017 as a venture and private-equity analyst and now oversees venture participations. He holds a corporate-finance master’s degree from Toulouse School of Management, with earlier experience at Legrand and Volkswagen’s risk division.

David Aversenq is a managing director and partner at M Capital. He joined its investment team in 2009 after corporate-finance and transaction-advisory work, including six years at PwC. He participated in the acquisition of the manager from Groupe BPCE and studied at Toulouse Business School.

David Richou is publicly listed by M Capital as Directeur d’Investissement - Immobilier. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Diane Fiocca is publicly listed by M Capital as Chargée d'Affaires. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Dina Raharolahy is publicly listed by M Capital as Comptable. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Estelle Adam joined M Capital in 2016 and manages legal matters for private debt and private equity. Her work includes fund creation, investments and exits. She holds business-law and DJCE qualifications and previously worked in a law firm and at Latécoère.

Fabrice Attané-Ferrand joined M Capital in 2019 for Fonds Tourisme Occitanie and moved into NACO deployment in 2022. His corporate-finance background includes PwC and Bpifrance, covering business financing, guarantees and investment products.

Florent Pouey is publicly listed by M Capital as Analyste Financier - Immobilier. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Florian Ricard joined M Capital’s private-debt team in 2019 for Fonds Tourisme Occitanie. He previously spent more than ten years supporting businesses and entrepreneurs at Crédit Agricole, HSBC and Banque Palatine.

François-Xavier Belliard is publicly listed by M Capital as Directeur Commercial. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Guillaume Gorski works on real-estate financial analysis, valuations, quarterly reporting and investor communications at M Capital. An ESPI graduate, he previously worked in Paris property investment, Montreal construction consulting and investment leadership at Wiseed.

Hortense Mellinger joined M Capital in 2012 and leads marketing and communications across its brand, investment products and portfolio activities. Her previous experience includes Dim, Pierre Fabre and e-commerce.

Jean-Baptiste Bourhis is publicly listed by M Capital as Responsable d'Investissement - Dette Privée. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Jean-Pierre Renaudin is identified by NACO as its president in a June18,2025 statement. His published account describes regional innovation, industrial development, business transmission and long-term territorial investment. The sourced NACO presidency is distinguished from the external M Capital deployment team; no unrelated namesake biography or additional political office is assumed.

Jessica Darmon joined M Capital in 2017 in accounting and compliance support and moved into fund operations in 2019. Her published biography describes a management and finance master’s degree, previous accounting-firm experience and operational support across numerous funds.

Julie Khaski leads private debt at M Capital. She joined in 2019 as an investment director for Fonds Tourisme Occitanie and specialises in financing public and private projects. The manager notes her 2023 France Invest recognition for women in private debt.

Julien Charles-Lavauzelle joined M Capital in 2016 and works on growth-capital and business-transmission investments and portfolio oversight. His published biography describes prior audit experience and membership of the manager’s investment committee.

Karine Maurel leads M Capital’s real-estate business. She joined in 2006 and works on property development, asset management and financing products, including Good Property. Her earlier professional experience includes KPMG, PwC and finance leadership at Sage.

Khaira Benyamina joined M Capital in 2019 and manages client and partner relationships. Her earlier professional experience includes ACOSS and the French Red Cross.

Lucie Berges-Rosa joined M Capital’s private-equity investment team in 2011 and subsequently worked on portfolio monitoring and valuation. She studied at Bordeaux Management School and completed an MBA at Wake Forest University.

Lucie Pelloux joined M Capital in 2014 and manages digital projects. Her background includes web and multimedia training, agency experience and webmaster responsibilities at Crédit Agricole.

Lucile Bardou joined M Capital in 2013 in accounting and became deputy secretary general in 2016. She supports fund operations, accounting and legal administration. Her qualifications include a master’s degree in management control and financial engineering.

Marc Trubert develops M Capital’s investment activities. He advised portfolio companies from 2014 and joined the private-equity team in 2019, later supporting Fonds Tourisme Occitanie. His earlier career included 23 years of operating and commercial responsibilities at France Boissons.

Marion Laurens joined M Capital in 2014 to support private-equity fund and investment legal work, then moved into property-financing legal responsibilities in 2017. She holds a postgraduate tax-law qualification and previously worked in a law firm.

Marius Branger is publicly listed by M Capital as Analyste Financier - Immobilier. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Maxime Sauvanet is publicly listed by M Capital as Directeur d’Investissement - Immobilier. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Murielle Rembliere is publicly listed by M Capital as Assistante Juridique. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Olivier Besançon joined M Capital in late 2020 for Fonds Tourisme Côte d’Azur. His background includes fifteen years in corporate and institutional banking at Arkéa and earlier industrial-sector financing. He studied at SKEMA in Sophia Antipolis.

Pierre Monnin is publicly listed by M Capital as Chargé d'Affaires - Private Equity. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Rudy Secco leads M Capital and its investment committees. He acquired the manager from Groupe BPCE and expanded its venture, private-equity, private-debt and property strategies. His earlier career included advisory leadership at KPMG, Arthur Andersen and EY; he studied at Toulouse Business School.

Stéphane Ferran joined M Capital in 2017 and is deputy managing director for real estate. An INSA-trained engineer, he previously worked for more than two decades in construction and property development, including SPIE, Akerys and DEDIA.

Stéphanie Minissier oversees finance and compliance at M Capital, including management-company and fund controls. Her previous experience includes Synercom, and her published qualifications include the DECF accounting diploma.

Théo Hernandez joined M Capital in 2017 as a portfolio analyst and moved into private-equity business development. He studied at Toulouse Business School and previously worked on borrower relationships and financing transactions at October.

Thibault Richebois is publicly listed by M Capital as Directeur Général - M Capital Nouvelle Aquitaine. The current directory identifies this professional function and an original portrait but publishes no detailed career biography; no additional qualifications or career history are assumed.

Founding scientist of NMD Pharma, with a 2008 Aarhus physiology and biophysics doctorate. Published research examines muscle sarcoplasmic-reticulum calcium transport and neuromuscular physiology. Founder status is distinguished from a current executive role.

Founding scientist of NMD Pharma. His Aarhus research focuses on skeletal-muscle channels and transporters and their roles in muscle function and fatigue. The published founder affiliation does not establish a current executive position.

NMD Pharma nonexecutive director since 2019. His biotech career includes Nido Biosciences CEO, Syros business leadership and Flagship Pioneering, after founding scientific and business-development work at Alexion. Holds degrees from Colby and Louisiana State University Medical Center.

Lundbeckfond Invest A/S, CVR21855545, is the Danish investment holding company wholly owned by the legally distinct Lundbeck Foundation, CVR11814913. The foundation’s audited group overview places Strategic Ownerships, Invest financial investments and Lundbeckfonden BioCapital within this company and identifies NMD Pharma as its associate. BioCapital is the internal evergreen biotech venture-investment unit, financing early through clinical-stage science-based companies; EMERGE was its earlier early-stage unit branding, with Christian E. Elling’s EMERGE managing-partner term January2017–March2022 and BioCapital role fromApril2022 documented in an issuer SEC proxy. The holding company’s public investment activities draw on twenty current named operational professionals across BioCapital, Invest and Strategic Ownerships; these are source-qualified unit affiliations rather than inferred separate payroll contracts or corporate directors. Foundation, legal holding company, internal unit brands and manufacturer H. Lundbeck A/S remain distinct. NMD investment participations are represented once under the actual holding-company buyer, with historical EMERGE/BioCapital branding retained in sources. The evergreen strategy uses foundation-owned capital; no external LP final close is inferred from portfolio values, commitments, ownership percentages or yearly investment totals.

Lundbeckfonden, the Lundbeck Foundation, is a Danish enterprise foundation established by Grete Lundbeck under statutes dated March4,1954, registered CVR11814913 and supervised by the Danish Business Authority. It funds Danish-based biomedical research, with a strong focus on neuroscience, clinical brain disorders, scientific talent and the Brain Prize. Its current public organisation publishes sixty operational staff and thirteen board members. The foundation wholly owns the legally distinct investment holding company Lundbeckfond Invest A/S, CVR21855545; strategic ownership, financial investments and BioCapital biotechnology investment operate within that holding structure. BioCapital’s predecessor EMERGE and the pharmaceutical manufacturer H. Lundbeck A/S are not the same legal foundation. Research grant awards, actual grant payouts, net wealth, investment portfolio market values and external fund closes are distinct measures; none is substituted as issuer equity financing or an LP fund raise.

NMD Pharma’s board chair since December 2022. A biopharma entrepreneur who founded Avenge Bio, Collegium Pharmaceutical and Precision Dermatology after beginning at Eli Lilly. He is a pharmacist with a Connecticut pharmacy degree. Board service does not establish a personal investment.

NMD Pharma’s Executive Assistant to the CEO since January 2023 and published ESG lead. Formerly developed institutional relations at British Patient Capital, with stakeholder-management and business-development experience. Holds a Surrey degree and investment-management qualifications.

NMD Pharma’s Vice President of Finance and IT since August 2024. Previous finance and digital-transformation work includes Danske Fragtmænd, EY and Novo Nordisk. Holds Aarhus finance, business and economics degrees.

NMD Pharma’s Senior Vice President, General Counsel and Head of People and Business Services since January 2024. Prior legal leadership includes LEO Pharma’s intellectual-property and R&D legal work and TDC. An attorney educated at Copenhagen with Seton Hall healthcare-compliance training.

NMD Pharma’s Senior Vice President of Corporate and Commercial Strategy since June 2023. Prior commercial leadership includes Catalyst Pharmaceuticals, Edge Therapeutics, Lundbeck US, Abbott and Eli Lilly. He holds Notre Dame and Northwestern Kellogg degrees.

NMD Pharma’s CMO since September 2025. A neurologist trained at Oviedo University, with development leadership at Santhera and Novartis spanning neurology and other therapeutic areas. Historical Jorge Quiroz CMO announcements do not override her current appointment.

Esther Crauser Delbourg is a publicly named current venture partner at GO Capital. Her official profile provides her affiliation and authentic portrait, while further career history and appointment dates remain undisclosed.

NMD Pharma’s COO since September 2019. Previously led global clinical operations at LEO Pharma, with earlier research, development and CMC leadership. Holds veterinary medicine and clinical pathology doctorate qualifications from Copenhagen.

Carlos Campos is a publicly named current venture partner at GO Capital, with Barcelona listed in his official profile. Additional career history and dates are not disclosed on that profile.

Laurent Sassier is a publicly named current venture partner at GO Capital. The official directory supplies his portrait and affiliation but does not disclose a career biography or appointment date.

NMD Pharma’s co-founder and CEO since 2015. His skeletal-muscle electrophysiology and ClC-1 ion-channel research at Aarhus University underpins its therapeutic platform. He holds an Aarhus doctorate and completed postdoctoral research at Cambridge.

NMD Pharma nonexecutive director and managing partner of Lundbeckfonden BioCapital, its evergreen biotechnology investment unit. Joined the foundation in 2012; previously co-founded and led 7TM Pharma. Holds a Copenhagen pharmacology doctorate. Corporate board membership is separate from any personal cash. Christian Elling is listed by the Lundbeck Foundation as Senior Vice President, Managing Partner Lundbeckfonden BioCapital. Joined foundation2012; University of Copenhagen biochemistry MSc and pharmacology PhD. Co-founded7TM Pharma, serving in biology/development leadership and later CEO. SEC biography documents EMERGE managing-partner termJanuary2017–March2022 and BioCapital fromApril2022. Exact current own name ChristianE.Elling; shared NMD board biography and portrait are preserved.

Erwan Jacquin is a publicly named current venture partner at GO Capital. The official directory provides his portrait and affiliation but no substantive career biography; outside positions and dates are not inferred.

NMD Pharma A/S is a Danish clinical-stage biotechnology company (CVR36899069), incorporated as an Aarhus University spin-out in2015, headquartered in Aarhus with US operations. It develops small-molecule therapies targeting skeletal-muscle chloride channel ClC-1 to improve neuromuscular transmission and muscle function. Its investigational lead ignaseclant, formerly NMD670, is being evaluated in Charcot-Marie-Tooth disease, generalized myasthenia gravis and spinal muscular atrophy. Additional research addresses age-related muscle weakness and sarcopenia. Its neuroscience relevance is neuromuscular biology and drug development; no unsupported claim that its platform is artificial intelligence is made. The current primary website publishes seven management members, fifty-nine other team members, eight board members including the CEO, and three founding scientists. Functions not published in the general team directory remain qualified as Team Member; founding-scientist status is distinct from current executive employment. Current CMO Ana de Vera joined September2025, superseding older Jorge Quiroz CMO announcements. Current board affiliations are separately sourced and do not establish personal cash investments. Actual primary funding includes a EUR2.7million seed investment in2016, a EUR38million SeriesA announced March23,2018, EUR35million financing announced February15,2022 (stage undisclosed in the issuer release), and EUR75million SeriesB announced November15,2023. A separate EUR629000 Innovation Fund Denmark grant was reported received November30,2020. The2014 EUR330000 pre-seed grant funded Aarhus University before incorporation and is not company financing. Historical2016–17 DKK44million cumulative support and later cumulative EUR155million or approximately USD180million statements are not separate new rounds. Closed company cash, grant awards, historical totals and currency renditions remain distinct.

Jean-Marc Herbert has been a GO Capital venture partner since 2016. A biochemist with pharmaceutical R&D experience at Sanofi, he worked on cardiovascular and thrombosis research and later global discovery. He co-founded AV-Care, which merged with Acticor in 2020, and has held biotechnology advisory and company leadership positions.

Éric Cozanet founded GO Capital in 2003 after telecommunications, software and innovation-investment experience in Europe and the United States. He is currently published as a venture partner and strategic adviser, supporting business development, entrepreneur-investor relations and investment committees.

Nathalie Peltier leads GO Capital’s compliance and internal-control function and is also listed as a partner. She previously worked in legal matters at SDR Bretagne and in back-office management at Bretagne Jeunes Entreprises. She joined GO Capital in June 2017.

Adeline Robbes joined GO Capital in May 2018 as back-office manager. She previously worked in banking operations and client relations, followed by financial and client-management roles in health insurance and social protection.

Anne-Sophie Hélias works in GO Capital’s communications and marketing function. Her prior experience includes advising companies and executives on communications strategy and implementation, with particular exposure to finance and legal services.

Yannez Robic joined GO Capital in 2025 after a back-office role at Bpifrance. She supports seed funds and Impact Océan Capital and participates in the firm’s ESG committee.

Capnova is the Danish investment-management company CAPNOVA A/S, CVR14353089, formerly Østjysk Innovation A/S, based in Aarhus. Its website dates its state-backed innovation activity to1998; this operational history does not establish the legal incorporation date. It financed approximately300 innovative startups until the state innovation scheme ended in2018, then managed the roughly110 remaining investments as an exit operator during2019–2023. Today it primarily manages Midtjysk Iværksætter Fond (MIF), which co-invests with validated business angels in innovative Central Denmark ventures and currently makes no new investments. The website distinguishes this management mandate from Capnova’s few retained proprietary holdings, naming Resother Pharma and Clearview Trade. Capnova is owned by its five published partners. Historical biotechnology, neuromuscular therapeutics, environmental sensing and university-spinout activity makes it relevant to the deep-tech and neuroscience audit; it is not presented as an actively deploying new company-investment programme. Public programme allocations and statutory capital are not closed LP commitments.

Flemming Würtz Andersen is a published partner and co-owner of Capnova, the Danish manager of Midtjysk Iværksætter Fond. Capnova’s own current roster identifies Flemming Andersen as Partner and Board Member. The same team card supplies this genuine portrait; precise personal appointment dates and a longer career biography are not published on these pages.

Jens Søndergaard is a published partner and co-owner of Capnova, the Danish manager of Midtjysk Iværksætter Fond. Capnova’s own current roster identifies Jens Søndergaard as Partner and Chair of the Board. The same team card supplies this genuine portrait; precise personal appointment dates and a longer career biography are not published on these pages.

Lars Stigel is a published partner and co-owner of Capnova, the Danish manager of Midtjysk Iværksætter Fond. Capnova’s own current roster identifies Lars Stigel as Director and Partner and Board Member. The same team card supplies this genuine portrait; precise personal appointment dates and a longer career biography are not published on these pages.

Martin Haahr Mikkelsen is a published partner and co-owner of Capnova, the Danish manager of Midtjysk Iværksætter Fond. Capnova’s own current roster identifies Martin Mikkelsen as Partner and Board Member. The same team card supplies this genuine portrait; precise personal appointment dates and a longer career biography are not published on these pages.

Ole Ostenfeldt Mathiesen is a published partner and co-owner of Capnova, the Danish manager of Midtjysk Iværksætter Fond. Capnova’s own current roster identifies Ole Mathiesen as Partner and Board Member. The same team card supplies this genuine portrait; precise personal appointment dates and a longer career biography are not published on these pages.

Charlène Lefeuvre joined GO Capital in 2025. She supports venture-fund administration and office management. The official profile does not disclose additional prior career details.

Aldo Torrisi is named in the pharmaceutical holding Mediolanum Farmaceutici’s June2020 own governance document as Statutory Auditor (historical, own2020 roster). The affiliation is a source-qualified historical board or statutory-auditor position. Exact current tenure and independently matched personal portrait or additional biography are unpublished; no unrelated homonymous career or cash investment is assumed.

Mario Botto Micca is publicly listed as Board Member at SocialFare Seed; Board Member — 2025 governance roster at SocialFare Impresa Sociale. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Marco Bracchetti is named in the pharmaceutical holding Mediolanum Farmaceutici’s June2020 own governance document as Statutory Auditor (historical, own2020 roster). The affiliation is a source-qualified historical board or statutory-auditor position. Exact current tenure and independently matched personal portrait or additional biography are unpublished; no unrelated homonymous career or cash investment is assumed.

Alberto Calori is named in the pharmaceutical holding Mediolanum Farmaceutici’s June2020 own governance document as Statutory Auditor (historical, own2020 roster). The affiliation is a source-qualified historical board or statutory-auditor position. Exact current tenure and independently matched personal portrait or additional biography are unpublished; no unrelated homonymous career or cash investment is assumed.

Théophile Gallon became a GO Capital venture analyst in September 2025 after two years of work-study experience with the firm. Educated at IGR Rennes, he supports sourcing, financial modelling and investment structuring, particularly for digital and deep-technology companies.

Luciana Andriuzzi is named in the pharmaceutical holding Mediolanum Farmaceutici’s June2020 own governance document as Board Member (historical, own2020 roster). The affiliation is a source-qualified historical board or statutory-auditor position. Exact current tenure and independently matched personal portrait or additional biography are unpublished; no unrelated homonymous career or cash investment is assumed.

Maria Cristina Del Bono is named in the pharmaceutical holding Mediolanum Farmaceutici’s June2020 own governance document as Board Member (historical, own2020 roster). The affiliation is a source-qualified historical board or statutory-auditor position. Exact current tenure and independently matched personal portrait or additional biography are unpublished; no unrelated homonymous career or cash investment is assumed.

Giovanni Ravina is publicly listed as Delegated Director — 2025 board roster at SocialFare Impresa Sociale. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Roberto Sacchi is named in the pharmaceutical holding Mediolanum Farmaceutici’s June2020 own governance document as Board Member (historical, own2020 roster). The affiliation is a source-qualified historical board or statutory-auditor position. Exact current tenure and independently matched personal portrait or additional biography are unpublished; no unrelated homonymous career or cash investment is assumed.

Valentin Fabre became a GO Capital analyst in September 2025 after an internship and works on the Sustainable Water Fund. He studied mechanical engineering at INSA Lyon and finance and impact entrepreneurship at ESSEC. His previous experience includes hydropower projects, banking and family-office private equity.

Aurora Castello is publicly listed as Investment Partner at SocialFare Seed. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Alessandro Del Bono is a pharmaceutical executive identified by Mediolanum Farmaceutici as its chief executive in the2020 governance disclosure and by transaction partner Ardian in2022. He also led Neopharmed Gentili, which is a distinct corporate business; role changes at that company are not automatically changes to the pharmaceutical holding. This record does not refer to the unrelated airline captain or other homonymous individuals.

Nicola Miglietta is publicly listed as Sole Statutory Auditor at SocialFare Seed; Sole Statutory Auditor — 2025 governance roster at SocialFare Impresa Sociale. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Mediolanum Farmaceutici S.p.A. is a privately owned Italian pharmaceutical holding and development group founded in Milan in 1972 by Rinaldo Del Bono. Its own legal disclosure identifies VAT/tax code 01689550158 and registered office Via San Giuseppe Cottolengo 15, Milan. It invests corporate resources in pharmaceutical research, licensing, co-development, acquisitions and strategic biotechnology stakes, with a current published emphasis on oncology and rare diseases. The pharmaceutical company is distinct from Mediolanum banking and asset-management businesses; no financial-manager merger is inferred from the shared name. Its historical scientific and commercial activities include cardiovascular treatments and a French expansion from 1990. Own history reports the 2020 ElsaLys Biotech acquisition for immuno-oncology development. Current published group structure names Istituto Gentili, Vamfarma, Laboratoires Leurquin and Mediolanum Biosciences, alongside property/hospitality businesses that are not treated as neuroscience portfolio companies. A 2022 transaction-party release separately confirms a retained significant minority interest in Neopharmed Gentili, a pharmaceutical business with neurology and cardiovascular products, after Ardian and NB Renaissance invested; family members’ separate personal stakes are not substituted for the corporate holding. The platform is a corporate investor, not a disclosed pooled venture fund. No corporate revenue, equity capital, partner fund assets, bond issued by a subsidiary or portfolio cash raise is imported as a new Mediolanum investment-fund close. The available own governance roster is the June 2020 published five-person board and three statutory auditors, recorded historically. Alessandro Del Bono’s group CEO role is additionally confirmed by its 2022 transaction partner, but exact current 2026 operating roster and tenure are unpublished. No genuine independently matched individual portraits were available from the reviewed own governance pages; no generic team photo or homonymous person image is substituted. Rinaldo Del Bono’s existing full biography, Acticor historical board affiliation and personal Investor10866/check remain unchanged. Source-proven corporate participation in Acticor’s June 2021 equity financing and March 2023 capital increase is separately linked after issuer verification; earlier licensing/co-development from 2016 does not prove a separate paid equity round. Acticor itself entered judicial liquidation in January 2025, so the holding’s historical investment is not a claim of current clinical efficacy or an approved stroke drug.

Malo Le Den joined GO Capital as a venture analyst in 2022. He sources opportunities and helps evaluate early-stage companies through investment committee review. His education includes a corporate-finance MSc at NEOMA.

Giulia Scagliarini is publicly listed as Board Member at SocialFare Seed; Board Member — 2025 governance roster at SocialFare Impresa Sociale. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Guillaume Loudenot joined GO Capital in September 2024 and covers Normandy from Caen. His career includes fundraising and M&A advice, creation of a Crédit Agricole regional venture fund and finance leadership at Yousign. He studied financial engineering and financial mathematics.

Wilma Tesio is publicly listed as Vice President at SocialFare Seed; Board Member — 2025 governance roster at SocialFare Impresa Sociale. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Andrea Limone is publicly listed as Board Chair at SocialFare Seed. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Filippo Psacharopulo is publicly listed as Chief Executive Officer at SocialFare Seed. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Salah Chattabi brings financial-audit experience from Deloitte and innovation-financing experience from Bpifrance. Based in Bordeaux, he evaluates opportunities and business financial structures for GO Capital. His education includes engineering, applied mathematics and statistics at Télécom SudParis.

Christine Hockley is named as Managing Director, Funds in British Patient Capital’s 2024 annual report, reporting on fund commitments, its core programme and specialist life-sciences fund strategy. This affiliation records the dated published BPC responsibility; current legal employment after the 2025 integration is not established.

David Edward Hourican is a currently registered director of British Patient Capital Limited, appointed on October 1, 2026. The affiliation is the statutory director office of that legal company; no unverified executive or investment responsibilities are added.

Emma Johnson authored British Business Bank’s February 2025 account of British Patient Capital’s life-sciences direct and co-investment activity, with the published title Senior Investment Manager, Life Sciences Direct and Co-investment. Her article explains growth-stage capital for biotech and healthcare businesses. The profile is qualified to that dated BPC responsibility; it does not infer subsequent employment status. Emma Johnson is Senior Principal at M Ventures. Joined the biotechnology team in2026 after healthcare direct investment at BritishBusinessBank and earlier venture experience. Co-founded InvestInEquity. Holds UCL cognitive-neuroscience MSc and Bristol neuroscience BSc; her dated2025 BPC affiliation remains preserved.

Esi Addae Eshun is the currently registered company secretary of British Patient Capital Limited, appointed on November 20, 2023. This is a statutory company-secretary office; no wider British Business Bank employment title is inferred.

Laura Orestano is publicly listed as Board Chair at SocialFare Impresa Sociale; Vice President at SocialFare Seed. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Leandros Kalisperas is a currently registered director of British Patient Capital Limited, appointed on February 1, 2025. This records the active company directorship, independently of any parent-group employment.

Thomas Matthew Horton is a currently registered director of British Patient Capital Limited, appointed on March 27, 2025. The affiliation is the statutory director office of that legal company; no executive investment or parent-employer title is inferred.

Tom Haywood was appointed Managing Director of Direct Investments at British Patient Capital in July 2024. His own appointment biography describes joining BPC in 2019, helping establish direct investments in Quantexa and Thought Machine, earlier investment work at Foresight and EcoMachines Ventures, and co-founding biotech manufacturing company Puridify, later acquired by GE Healthcare. The recorded title is qualified to the dated BPC announcement.

François Fauvin joined GO Capital in 2021, progressing from analyst to investment associate. He works on Mer Invest and maritime companies, supporting investment analysis and portfolio development. He previously worked in audit at EY and studied financial data intelligence at Rennes School of Business.

Giulia Terracciano is publicly listed as Public Private Partnership Expert at SocialFare Impresa Sociale. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Julien Louis joined GO Capital in March 2023 and works on Odiem Capital. He previously advised on transactions at Oderis and worked in financial control at Thom Europe. His education includes KEDGE and study at the University of St Gallen.

Margot Boulanger worked on innovation strategy at SUEZ and on agriculture and food-chain innovation at Veolia. Her education combines environmental engineering at AgroParisTech with environmental policy at Sciences Po. She is published as a senior associate at GO Capital.

Damien Jouanneau brings corporate-finance and investment experience from Deloitte and Ouest Croissance. His work includes growth capital, buyouts and venture investments in French businesses, with an emphasis on governance and environmental transition. He holds an IFA/Audencia corporate-director certification.

Clémentine Pécastaing is the current directory name; the same official biography and profile URL retain the earlier name Clémentine Breysse. She joined GO Capital in October 2021 to support Sud Mer Invest in Marseille. Her work covers sourcing, investment negotiations and portfolio monitoring, building on financial-analysis and fundraising experience.

Alexandre Boulay joined GO Capital in June 2020, focusing on healthcare and deep technology. He previously worked in innovation consulting and technology transfer at SATT Ouest Valorisation. His education combines a chemistry/health doctorate with technology innovation management and finance.

Anne Toupé joined GO Capital in February 2023 after a career at BNP Paribas. She helped develop innovation financing at Massy-Saclay and later invested through BNP Paribas Développement’s venture unit. She holds a Bordeaux master’s degree in banking, finance and international trade.

Maria Cristina Porta served as Director General of Fondazione ENEA Tech e Biomedical fromMay1,2023 throughJuly15,2026, according to the official transparency record updated September30,2026. Her source-published CV describes earlier leadership of incubation and open innovation at ComoNExT from2013 to2023 and service on the foundation board from2022. The current director general is Stefano Massari; older CV language is retained as historical professional context.

Massimo Caon is the publicly named Acceleration Expert responsible for deal flow at SocialFare, the Italian social innovation enterprise and startup accelerator. Massimo Caon is publicly listed as Acceleration Expert — Deal Flow at SocialFare Impresa Sociale. SocialFare works in systemic design, social innovation and impact-focused startup acceleration; SocialFare Seed is its separate corporate seed investment vehicle. Dated 2025 governance titles are identified as such, rather than inferred current executive appointments. The official directory supplies the named authentic portrait; it does not publish a detailed career biography, so prior employers or investment tickets are not inferred.

Daniela Skendaj holds the published foundation role of Director of Institutional and International Relations, effective 2022-04-04, according to the current official transparency record. Her official CV identifies an Italian-Albanian legal professional with public, private and nonprofit experience, leading institutional partnerships and relations with biomedical, pharmaceutical and technology stakeholders.

Guillaume Foillard joined GO Capital in 2024 to manage the Sustainable Water Fund. He previously worked in transaction services, private equity and environmental investments at Arthur Andersen, IPO, Lazard/LFPI and Turenne. His investing experience spans growth capital and buyouts of European businesses.

Mario Poti holds the published foundation role of Director of Communications, effective 2023-05-29, according to the current official transparency record. His official CV describes communications and external-relations experience including Eurispes and the Italian Customs and Monopolies Agency before joining the foundation.

Carmela Notaro holds the published foundation role of Director of Projects, Investments and Portfolio Development, effective 2024-10-01, according to the current official transparency record. Her source-published earlier CV describes more than20years in investment appraisal, feasibility studies, business plans, economic impact and public-programme finance, including work in PwC Capital Projects. The older CV job title is historical rather than substituted for the current foundation appointment.

Frédéric Le Guillou joined GO Capital in 2015 and focuses on maritime businesses and environmental transition. He previously worked with investment clubs and co-founded a foodtech company. His education includes agricultural engineering at Institut Agro and entrepreneurship at EMLyon.

Caterina Flick holds the published foundation role of Director of Legal Affairs, effective 2024-09-02, according to the current official transparency record. Her official CV records leadership of legal affairs at Agenzia per Italia Digitale fromSeptember2021 toAugust2024, with legal and regulatory work on digital transformation, accessibility, digital trust services and public contracting.

Angela Della Torre holds the published foundation role of Director of Procurement and Contracts, effective 2025-09-01, according to the current official transparency record. Her official CV describes procurement planning, tender procedures, qualified contracting-authority responsibilities and management of the foundation procurement team, following service in its procurement office fromSeptember2023.

Frédéric Le Brun joined GO Capital in 2022 after corporate turnaround, technology operations and venture-capital roles. His career includes Arthur Andersen, Devoteam, Natixis Private Equity, Bpifrance’s digital venture team and Metro AG’s corporate venture platform. He studied at ESCP.

Alexis Ménard joined GO Capital in early 2017. He previously worked in supply-chain operations at Procter & Gamble, founded a last-mile logistics startup and advised companies on digital transformation. He trained at INSA Lyon, HEC Paris and ESSEC.

Carmelo Catalano holds the published foundation role of Director of Administration, Finance and Control, effective 2023-07-01, according to the current official transparency record. Financial planning, financial modelling, accounting and investment business plans; his official career history includes CFO of Infrarail in the Ferrovie dello Stato group from2020 to2023.

Alberto Corbello is publicly named by Fondazione Tech e Biomedical in its current governance roster as Auditor. The private nonprofit foundation, formerly ENEA Tech e Biomedical, administers technology-transfer and biomedical-development mandates under Italian ministerial oversight. This affiliation is a governance or statutory-control role, distinct from ordinary operating staff or personal financing.

Andrea Donnini is publicly named by Fondazione Tech e Biomedical in its current governance roster as Chair of the Board of Auditors. The private nonprofit foundation, formerly ENEA Tech e Biomedical, administers technology-transfer and biomedical-development mandates under Italian ministerial oversight. This affiliation is a governance or statutory-control role, distinct from ordinary operating staff or personal financing.

IAG publishes Anna Di Silverio as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Business Advisor. Digital Anna è una leader riconosciuta a livello internazionale nella strategia digitale e nell’implementazione di soluzioni tecnologiche innovative, con ampia esperienza nella guida di programmi di trasformazione organizzativa volti all’efficienza operativa e alla crescita. Ha guidato organizzazioni complesse in Europa, Asia e Sudamerica, ottenendo risultati di crescita significativi. La sua combinazione di visione strategica, rigore esecutivo e conoscenza tecnologica la rende un punto di riferimento per le organizzazioni che vogliono evolvere rapidamente e in modo sostenibile.

IAG publishes Antonella Fanuzzi as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Senior Advisor e Investor. Digital C-level executive, senior advisor e membro di board con oltre 17 anni di esperienza nei settori digital, tech, media e industriale. Ha guidato organizzazioni come Google, Italiaonline e Amplifon, con focus su crescita, trasformazione digitale e strategie go-to-market. Attivo anche nell’ecosistema startup come advisor e investitore.

David Leray is a digital entrepreneur and investor. He founded Sitimmo, later named Ubiflow, and Vacances.com, which was acquired by Axel Springer. He continued to manage Vacances.com after the acquisition and studied marketing at IAE-IGR Rennes. His personal investment history does not establish particular personal checks here.

IAG publishes Lamberto Siega as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Digital & Media Executive. Digital Lamberto vanta oltre 20 anni di esperienza manageriale nei settori Media, Digital, Entertainment e Sport. Ha lavorato per BCG, eBay, Mediaset e AC Milan, ed è appassionato dell’incontro tra sport, tecnologia e media.

Mario Giovanni Patti is publicly named by Fondazione Tech e Biomedical in its current governance roster as Auditor. The private nonprofit foundation, formerly ENEA Tech e Biomedical, administers technology-transfer and biomedical-development mandates under Italian ministerial oversight. This affiliation is a governance or statutory-control role, distinct from ordinary operating staff or personal financing.

IAG publishes Mattia Marone as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Business Development. Digital Membro del Consiglio di Amministrazione di Resistor S.r.l., azienda manifatturiera nel settore automotive. Si occupa di analisi finanziaria, pianificazione strategica e supporto a operazioni di crescita, con focus su corporate finance, M&A e investimenti immobiliari. Coinvolto anche nello sviluppo di un centro sportivo polifunzionale.

IAG publishes Rosita Mainieri as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Senior Sales Executive. Digital Senior Digital Executive con solida esperienza nella guida di organizzazioni globali attraverso complessi percorsi di AI e trasformazione digitale. Possiede un profilo multidisciplinare unico che unisce ingegneria (profondità tecnica), un MBA (strategia di business) e filosofia (focus sull’etica della GenAI). Vanta ampia esperienza nella consulenza strategica e nel demand management per clienti C-suite in diversi settori.

IAG publishes Francesco Murras as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Imprenditore. Digital Da oltre 20 anni lavora nel settore immobiliare e dell’edilizia, di cui è appassionato. Diplomato e abilitato come Geometra, ha ricoperto diversi ruoli, da dipendente a libero professionista e imprenditore.

IAG publishes Michela Colli as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Imprenditrice. Digital Ha conseguito la laurea in Economia e Commercio presso l’Università Cattolica di Milano e ha iniziato la carriera in Deloitte & Touche e nello Studio Tremonti. Nel 1995 ha fondato TWT, guidandone la crescita fino a 100 milioni di euro, e successivamente altre startup nei settori tech e immobiliare. Nel 2023 ha gestito la cessione di TWT a Unidata S.p.A. Attualmente guida Upperhand Srl e il suo family office, sostenendo innovazione e nuova imprenditoria.

IAG publishes Nicola Marone as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Amministratore Delegato. Digital Amministratore Delegato di Resistor S.r.l. da oltre 30 anni, azienda manifatturiera specializzata in componenti automotive per motori diesel. Ha guidato la crescita dell’impresa attraverso sviluppo industriale e operazioni di M&A. Parallelamente, opera nel settore immobiliare e nello sviluppo di iniziative imprenditoriali, tra cui un centro sportivo polifunzionale in fase di realizzazione.

IAG publishes Roberto Liuzza as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Consulenza Strategica per la Trasformazione Aziendale. Digital 20 anni di esperienza nella consulenza di management e 10 anni in ruoli executive in aziende corporate. Investitore selettivo in private equity e startup.

Stefano Massari is a current member of the Fondazione Tech e Biomedical Governing Board and Director General effective July16,2026, as confirmed by the current own governance directory and the official transparency record updated September30,2026. He succeeded the prior published director general after the July leadership transition. His roles are separately recorded; no unsupported outside executive career or personal investment is inferred.

IAG publishes Gianluca Graziosi as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Senior Manager. Life Science Attualmente Senior Manager in Roland Berger, dove supporta clienti corporate e fondi di private equity con un focus sui settori healthcare e industrials. In precedenza ha maturato circa otto anni di esperienza in ambito corporate finance e M&A, ricoprendo ruoli sia di advisory sia di corporate development. Appassionato di investimenti, ha iniziato ad investire in startup nel 2016 e, più recentemente, ha ampliato il proprio interesse ai search fund. Gianluca è laureato in Economia e Management presso la Luiss Guido Carli e ha conseguito un MBA presso INSEAD. È abilitato alla professione di Dottore Commercialista.

IAG publishes Massimo Bravin as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Startup Incubator, Business and Financial Advisor. Digital

IAG publishes Matteo Frosi as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Consulente fiscale. Digital Dottore Commercialista e CEO di Turnaturi Frosi & Partners STP – Società Benefit. Supporta PMI, startup e professionisti nella pianificazione fiscale strategica, nella governance, nella protezione patrimoniale e nella strutturazione societaria orientata alla crescita. Si occupa inoltre di valutazioni d’azienda, analisi economico-finanziaria, ESG e valorizzazione di asset intangibili, con esperienza diretta anche come investitore in startup innovative.

IAG publishes Walter Comelli as an external angel-network member. The member profile describes the following career and investing background, whose corporate positions are not independently asserted current: Investor and Senior Business Advisor. Life Science Bolognese, laureato in Economia all’Alma Mater nel 1986. Dopo le prime esperienze in IBM e Volvo, ho conseguito un MBA alla UCLA per entrare nel mondo della finanza. Ho lavorato in Price Waterhouse e poi per oltre 20 anni nel Private Equity, in realtà come S+R, 3i plc e Imi Fondi Chiusi. Ho poi scelto il management diretto in UnipolSai, dove ho guidato il rilancio di Atahotels e il lancio di Dyadea. Da un anno opero come investitore e Senior Business Advisor.